drugset / Trial / NCT02467400

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400

Phase 0 Completed 165 enrolled Mayo Clinic
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

Timeline

Start
2015-07-01
Primary completion
2017-10-26
Completion
2018-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atenolol Other / unclassified 50 mg
Comparator Nebivolol Other / unclassified 5 mg
Comparator Propranolol Small molecule 20 mg
Comparator Propranolol Small molecule 40 mg